Sign up
Pharma Capital
EPIC: REDX
Market: AIM
52-week High/Low: 28.63p / 3.50p
Sector: Pharma & Biotech
Market Cap: 11.70M
Website: RedxPharma.com

Redx Pharma is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high unmet medical need, in cancer, immunology and infection. By improving the characteristics of existing drug classes, we aim to create differentiated, novel drugs.

Redx has an established portfolio of proprietary drug programs that it is developing alone and in...

Redx Pharma Plc

RedxPharma.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Redx Pharma Plc

Redx Pharma Plc Snapshot

Redx Pharma (formed in September 2010) has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.

 

Redx Anti-Infectives 

Redx Anti-Infectives Ltd is a wholly-owned subsidiary of Redx Pharma, a UK-based company discovering and developing new therapeutics for the global pharmaceutical market.

Redx has successfully applied its proprietary Redox Switch™ approach in the area of infectious disease generating a pipeline of novel antibacterial and antiviral drugs.

The recent calls from the World Health Organisation and the UK's Chief Medical Officer for greater efforts to be invested in the discovery of new antibiotics have highlighted the chronic lack of new therapies in this area. Redx Anti-Infectives, in collaboration with its partners, is playing its part in tackling this issue with a key focus on developing drugs to combat antibiotic resistance.

Application

Antibacterials

Although sales of anti-infective drugs represent around 11% of the global pharmaceutical market, every year 25,000 people in the EU die as a result of a serious drug resistant infection – mostly acquired in healthcare settings. The WHO has launched a major initiative to urge governments and the pharmaceutical industry to promote new R&D efforts to develop new anti-infective medicines.

There is a chronic need for new and novel antibacterial agents, particularly to address those increasingly prevalent organisms with inherent natural resistance to current antimicrobials (eg Acinetobacter baumannii) and those acquiring new resistance mechanisms (eg E. Coli and Klebsiella spp.). Redx Anti-Infectives is applying the company's proprietary Redox Switch™ platform to tackle this critical medical need.

Redx has rapidly generated a pipeline of programs that seek to address drug resistance. We are pursuing both broad and narrow spectrum approaches against Gram-positive and Gram-negative organisms.

Antivirals

Drug resistance to current small molecule influenza therapies is a growing problem that seriously threatens our ability to cope with future pandemic flu outbreaks.

By employing its novel Redox Switch™ chemistry approach, Redx Anti-Infectives is generating new candidate drugs with activity against both resistant and wild-type influenza strains.

Application

Antibacterials

Although sales of anti-infective drugs represent around 11% of the global pharmaceutical market, every year 25,000 people in the EU die as a result of a serious drug resistant infection – mostly acquired in healthcare settings. The WHO has launched a major initiative to urge governments and the pharmaceutical industry to promote new R&D efforts to develop new anti-infective medicines.

There is a chronic need for new and novel antibacterial agents, particularly to address those increasingly prevalent organisms with inherent natural resistance to current antimicrobials (eg Acinetobacter baumannii) and those acquiring new resistance mechanisms (eg E. Coli and Klebsiella spp.). Redx Anti-Infectives is applying the company's proprietary Redox Switch™ platform to tackle this critical medical need.

Redx has rapidly generated a pipeline of programs that seek to address drug resistance. We are pursuing both broad and narrow spectrum approaches against Gram-positive and Gram-negative organisms.

Antivirals

Drug resistance to current small molecule influenza therapies is a growing problem that seriously threatens our ability to cope with future pandemic flu outbreaks.

By employing its novel Redox Switch™ chemistry approach, Redx Anti-Infectives is generating new candidate drugs with activity against both resistant and wild-type influenza strains.

Redx Oncology

Redx Oncology was the first subsidiary formed by parent company Redx Pharma in April 2012. With over 190 people Redx Pharma is now one of the largest R&D pharmaceutical biotech employers in the UK and over 80 of these staff work within Redx Oncology. The company currently has a broad portfolio of novel oncology programs including three nominated development candidates (Btk, SMO, porcupine).

Redx Oncology works on small molecule approaches to cancer medicines with a focus on targeted medicines which will address key areas of unmet need such as pancreatic cancer, as well as developing second generation medicines which will treat emerging resistance to current therapies. The company also has a portfolio of immune-oncology programs which look to harness the immune system to fight the cancer. This is an area of cancer research which is showing great promise and is expected to become a key aspect of cancer therapy approaches in the future. The early results with launched antibodies such as the anti-PD-1 (Keytruda, Opdivo) and anti-CTLA-4 (Yervoy) have created a stir in the cancer research field but much remains to be done in terms of improving response rates so that this approach can benefit a wider patient population. Redx Oncology is working to develop small molecule drugs for use in combination with these antibodies to enhance their efficacy and increase the number of people who respond to treatment.

Redx Immunology

Redx Pharma announced the launch of its third subsidiary, Redx Immunology, in May 2015. The company will focus on developing new therapies for disorders of the immune system.

It is intended that Redx Immunology will deliver up to eight new drug development candidates over the near to medium term for subsequent progression into clinical trials. The launch of Redx Immunology is in line with the Group's stated strategy to develop a third therapeutic area to generate additional pipeline assets for further partnering and licencing deals. Its creation also complements Redx's current cancer-related drug programs which encompass immuno-oncology.

Redx Immunology's approach to drug discovery and development will be consistent with the Company's existing approach in its cancer and anti-infectives subsidiaries. It will focus on commercially relevant targets and seek to improve the characteristics of existing drug classes to create highly differentiated best-in-class new drugs. As with its other subsidiaries, Redx will seek partnership and licence deals at an early stage in drug development programs.

Ian Ross, Chairman
Iain Ross was appointed Non-Executive Chairman of Redx in May 2017 assuming the role of Executive Chairman in October 2017. In addition, he is Chairman of e-Therapeutics plc (AIM:ETX) and Novogen Ltd (ASX: NRT / NASDAQ:NVGN) and also a Non-Executive Director of Anatara LifeSciences Ltd (ASX:ANR). He is a qualified Chartered Director, and a Former Vice Chairman of the Council of Royal Holloway, London University.

Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the Company public, signing numerous collaborations before selling the business to Elan in 2001. As Chairman and Chief Executive Officer, at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. He continues to consult for private equity groups on biotech & technology company turnarounds.


Lisa Anson, Chief Executive Offier
Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018.

Lisa has been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a California based cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.

Lisa is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.


Dr Bernhard Kirschbaum, Non-Executive Director

Bernhard Kirschbaum joined the Board in January 2016. Bernhard has over 25 years’ experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company’s R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently Chairman of Protagen Diagnostics and a board member of BioMedX and OMEICOS Therapeutics.


Peter Presland, Non-executive Director

Peter Presland has nearly 45 years’ experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King’s College, London, he also qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc, a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the youngest ever PLC Director when appointed Group Finance Director at the age of 34. He was promoted to become Heath’s Group Chief Executive in 1990, and in 1996, he devised the demerger of C E Heath’s computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Executive Chairman. Shareholders doubled their money in three years. Since 2001, Peter has pursued a portfolio non-executive career. These appointments include the Chairmanship in 2003 of LINK, the UK ATM network, where he led a major corporate governance change and completed the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. From 2012 to 2015, he served as Chairman of the Audit and Governance Committee of East Kent Hospitals NHS Trust and has recently joined the Audit, Governance and Nominations Committee of The Lord’s Taverners, a high-profile charity.

Shareholders with >3% of total issued:

Name Number of shares Percentage of
issued shares
Seneca Partners 15,792,781 12.49%
Moulton Goodies Ltd 13,643,107 10.79%
Axa Investment Managers 12,417,336 9.82%
Lanstead Capital LP 12,075,000 9.55%
Aviva Plc 10,644,816 8.42%
Graham Edwards 3,999,900 3.16%

Last updated 18/04/17

Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG

 

Business Development

Nicholas Adams
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

01625 238 972

 

Investor Relations

Karl Hård
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

+44 7491 651 406

 

Human Resources

Redx Pharma HR
PO Box 707
Wakefield
WF1 9PJ

01924 566 080

 

Financial PR

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

020 3709 5700

 

Public Relations

Chris Hulme
Influential
5th Floor, Oxford Place
61 Oxford Street
Manchester
M1 6EQ

0161 804 1400

Nominated Adviser & Broker
Cantor Fitzgerald Europe
One Churchill Place
London E14 5RB, UK

Joint Broker
WG Partners LLP
85 Gresham Street
London EC2V 7NQ, UK

Corporate Finance Adviser
Acceleris Capital Ltd
Lowry House
17 Marble Street
Manchester M2 3AW, UK

Auditor
RSM UK Audit LLP
3 Hardman Street
Manchester M3 3HF, UK

Legal Advisers
Covington and Burling LLP
265 Strand
London WC2R 1BH, UK

DWF LLP
1 Scott Place
2 Hardman Street
Manchester M3 3AA, UK

Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK

 

View full REDX profile View Profile
View All

Columns Including REDX

VIEW ALL

Market Reports Including REDX

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.